Want to see LQDA full AI Analyst Report?
LQDA Stock Chart & Stats
$39.47
<$0.01(<0.01%)
At close: 4:00 PM EST
$39.47
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$16.82 - $89.51
Previous CloseN/A
Volume97.81K
Average Volume (3M)2.07M
Market Cap
$7.19B
Enterprise Value$3.78K
Total Cash (Recent Filing)$222.79M
Total Debt (Recent Filing)$184.82M
Price to Earnings (P/E)363.2
Beta1.56
Next Earnings
Aug 06, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding88,928,100
10 Day Avg. Volume1,253,779
30 Day Avg. Volume2,069,173
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$75.14Price Target Upside90.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)3.3
Revenue Forecast (FY)$721.88M
Bulls Say, Bears Say
Bulls Say
Commercial TractionRapid, repeatable commercial uptake for YUTREPIA—backed by strong early sales and conversion—creates a durable recurring revenue base. Sustained prescription growth and a growing prescriber base lower launch risk, fund reinvestment in manufacturing/clinical programs, and improve predictability of cash flows over the next 2–6 months.
Cash GenerationThe shift to positive operating and free cash flow marks a structural improvement in funding capacity. Positive FCF supports self-funding of manufacturing expansion and pivotal trials, reduces reliance on capital markets, and gives management flexibility to invest in commercialization and pipeline execution over the medium term.
Market Share & Prescriber DepthStrong early market penetration and increasing prescriber depth signal a competitive foothold in inhaled prostacyclins. High repeat-prescriber counts indicate clinician confidence and switching momentum, which can create durable share gains and raise barriers to competitor entry as the company scales sales and education efforts.
Bears Say
Patent Litigation RiskPending patent litigation is a structural business risk: adverse rulings or injunctions could restrict sales, require licensing payments, or delay launches. Legal uncertainty can deter some payers/partners and add planning risk for commercialization and long-term revenue forecasts until resolved.
Sizable Debt LoadAlthough leverage has improved, meaningful outstanding debt constrains financial flexibility and raises interest and covenant risk. Continued investment in commercialization and clinical programs will need to be balanced with debt servicing, which could limit capital allocation options if cash generation weakens.
Adoption & Dosing ConvenienceCapturing broader PH-ILD and community markets requires sustained education and diagnosis improvements; YUTREPIA's four-times-daily dosing may slow uptake in some settings. Management's L606 (twice-daily) is a structural mitigant, but its development/timing introduces execution risk for expanding addressable share.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies’s price range in the past 12 months?
Liquidia Technologies lowest stock price was $16.82 and its highest was $89.51 in the past 12 months.
What is Liquidia Technologies’s market cap?
Liquidia Technologies’s market cap is $7.19B.
When is Liquidia Technologies’s upcoming earnings report date?
Liquidia Technologies’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.
How were Liquidia Technologies’s earnings last quarter?
Liquidia Technologies released its earnings results on May 11, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11.
Is Liquidia Technologies overvalued?
According to Wall Street analysts Liquidia Technologies’s price is currently Undervalued.
Does Liquidia Technologies pay dividends?
Liquidia Technologies does not currently pay dividends.
What is Liquidia Technologies’s EPS estimate?
Liquidia Technologies’s EPS estimate is 0.76.
How many shares outstanding does Liquidia Technologies have?
Liquidia Technologies has 88,928,100 shares outstanding.
What happened to Liquidia Technologies’s price movement after its last earnings report?
Liquidia Technologies reported an EPS of $0.52 in its last earnings report, beating expectations of $0.41. Following the earnings report the stock price went up 25.603%.
Which hedge fund is a major shareholder of Liquidia Technologies?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.14 (90.38% Upside)
$75.14 (90.38% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 25.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $114.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
424.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
76.55%
Trailing 12-Months
Company Description
Liquidia Technologies
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
LQDA Stock 12 Month Forecast
Average Price Target
$75.14
▲(90.38% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
30.65% Insiders
8.46% Mutual Funds
0.31% Other Institutional Investors
42.49% Public Companies and Individual Investors